Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

被引：1
|
作者：
Flora, Darcy R. [1 ]
Parsons, Susan K. [2 ]
Liu, Nicholas [3 ]
Yu, Kristina S. [3 ]
Holmes, Katie [4 ]
Flores, Carlos [5 ]
Fanale, Michelle A. [3 ]
Kumar, Supriya [4 ]
Surinach, Andy [5 ]
Byrd, Rachel [1 ]
Evens, Andrew M. [6 ]
机构：
[1] GRYT Hlth, Rochester, NY USA
[2] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA
[3] Seagen Inc, Bothell, WA USA
[4] Ipsos Healthcare, New York, NY USA
[5] Genesis Res, Hoboken, NJ USA
[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147354
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1966
引用
收藏
页码：1966 / +
页数：4
相关论文
共 50 条
  • [41] Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 US Academic Centers
    Voorhees, Timothy
    McLaughlin, Eric
    Torka, Pallawi
    Florindez, Jorge A.
    Moyo, Tamara K.
    Reves, Heather
    Sumransub, Nuttavut
    Deshpande, Saarang
    Rose, Ashley
    Duarte, Cassandra
    Faisal, Muhammad Salman
    Hamid, Showkat
    Subbiah, Suki
    Ayyappan, Sabarish R.
    Shea, Lauren Kelly
    Cortese, Matthew J.
    Patel, Krish
    Major, Ajay
    Saeed, Hayder
    Svoboda, Jakub
    Desai, Sanjal H.
    Geethakumari, Praveen Ramakrishnan
    Grover, Natalie S.
    Epperla, Narendranath
    BLOOD, 2023, 142
  • [42] Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians
    Price, David
    Harrow, Brooke
    Small, Mark
    Pike, James
    Higgins, Victoria
    WORLD ALLERGY ORGANIZATION JOURNAL, 2015, 8
  • [43] Differences in Non-Hodgkin Lymphoma (NHL) patients with and without femur fracture in patients age < 65 versus > 65 years - results from a cross-sectional study
    Reske, T.
    Cefalu, C.
    Loch, M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2014, 62 : S45 - S45
  • [44] THE SWITCH FROM ABVD TO eBEACOPP AS FRONT-LINE THERAPY FOR HIGH-RISK STAGE III-IV CLASSICAL HODGKIN LYMPHOMA PATIENTS RESULTS IN AN INVERSION OF EVENT-FREE SURVIVAL OF PROGNOSTIC GROUPS
    Aurer, I.
    Basic-Kinda, S.
    Dujmovic, D.
    Radman, I.
    Dreta, B.
    Dotlic, S.
    Galunic-Bilic, L.
    Dobrenic, M.
    Kralik, M.
    Roncevic, P.
    HAEMATOLOGICA, 2016, 101 : 24 - 24
  • [45] Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
    Sikirica, Mirko V.
    Martin, Alan A.
    Wood, Robert
    Leith, Andrea
    Piercy, James
    Higgins, Victoria
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2017, 10 : 403 - 412
  • [46] First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial
    Rossi, Cedric
    Marouf, Amira
    Fischer, Benedicte Deau
    Cherblanc, Fanny
    Cugnod, Emeline
    Chartier, Loic
    Fornecker, Luc Matthieu
    Andre, Marc
    Casasnovas, Rene-Olivier
    Ghesquieres, Herve
    BLOOD, 2023, 142
  • [47] Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490)
    Radford, John
    Dlugosz-Danecka, Monika
    Connors, Joseph M.
    Illes, Arpad
    Picardi, Marco
    Lech-Maranda, Ewa
    Feldman, Tatyana
    Smolewski, Piotr
    Savage, Kerry J.
    Bartlett, Nancy L.
    Walewski, Jan
    Ramchandren, Radhakrishnan
    Zinzani, Pier Luigi
    Hutchings, Martin
    Munoz, Javier
    Kim, Won Seog
    Advani, Ranjana
    Ansell, Stephen M.
    Younes, Anas
    Gallamini, Andrea
    Liu, Rachael
    Little, Meredith
    Fenton, Keenan
    Fanale, Michelle
    Straus, David J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 145 - 147
  • [48] BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490)
    Picardi, M.
    Straus, J.
    Dlugosz-Danecka, M.
    Connors, J. M.
    Illes, A.
    Lech-Maranda, E.
    Feldman, T.
    Smolewski, P.
    Savage, K. J.
    Bartlett, N. L.
    Walewski, J.
    Ramchandren, R.
    Zinzani, P. L.
    Hutchings, M.
    Munoz, J.
    Kim, W. S.
    Advani, R.
    Ansell, S. M.
    Gallamini, A.
    Liu, R.
    Little, M.
    Fenton, K.
    Fanale, M.
    Radford, J.
    HAEMATOLOGICA, 2021, 106 (10) : 44 - 44
  • [49] Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation
    Savage, Kerry J.
    Connors, Joseph M.
    Villa, Diego R.
    Hapgood, Greg
    Gerrie, Alina S.
    Shenkier, Tamara N.
    Scott, David W.
    Gascoyne, Randy D.
    Benard, Francois
    Morris, James
    Pickles, Tom
    Parsons, Christina
    Wilson, Don
    Sehn, Laurie H.
    BLOOD, 2015, 126 (23)
  • [50] Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers
    Annunzio, Kaitlin
    McLaughlin, Eric
    Voorhees, Timothy
    Shea, Lauren Kelly
    Sumransub, Nuttavut
    Rose, Ashley
    Olszewski, Adam J.
    Bailey, Neil
    Patel, Krish
    Moyo, Tamara K.
    Awan, Farrukh T.
    Ahmed, Gulrayz
    Grover, Natalie S.
    Adika, Adam
    Andres, Erica L.
    Faisal, Muhammad Salman
    Christian, Beth
    Anna, Jacob
    Bair, Steven M.
    Kendsersky, Nicholas
    Thomas, Colin
    Torka, Pallawi
    Svoboda, Jakub
    Carter, Jordan S.
    Hamadani, Mehdi
    Saeed, Hayder
    Desai, Sanjal H.
    Evens, Andrew M.
    Epperla, Narendranath
    BLOOD, 2023, 142
12345